Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADU-S100 + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intratumoral
01
Overview
ADU-S100 + pembrolizumab is an investigational combination therapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). ADU-S100 (MIW815) is a synthetic cyclic dinucleotide that acts as an agonist of the stimulator of interferon genes (STING) pathway, leading to innate immune activation and enhanced anti-tumor immunity. Pembrolizumab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, restoring T-cell activity against tumor cells. The combination aims to synergistically boost immune responses against cancer by activating both innate (via STING) and adaptive (via PD-1 inhibition) immune pathways[1][3][5]. ADU-S100 is administered by intratumoral injection; pembrolizumab is given as an intravenous infusion. The development program was sponsored by Chinook Therapeutics (formerly Aduro Biotech), and clinical trials involved a research partnership with Novartis. Development status for this combination in HNSCC is Phase 2, but trials have been discontinued due to lack of substantial antitumor activity[5][3].
- Other names
- ADU-S100 + KeytrudaMIW815 + pembrolizumab
02
Targets
STING (Stimulator of interferon genes protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ADU-S100 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADU-S100 + pembrolizumab.